If you now feel like your body has quietly rewritten its own rulebook — the same workouts that used to work don’t, the scale creeps up around your midsection, and willpower alone just isn’t cutting it anymore — you are not imagining things, and you are not failing.
Perimenopause and menopause bring real hormonal shifts (falling estrogen, insulin resistance, slower metabolism, redistributed fat) that make weight loss biologically harder, not just psychologically harder.
That’s exactly why a class of injectable medications — retatrutide, tirzepatide, and semaglutide — has become one of the most talked-about developments in medicine.
They don’t just suppress appetite; they work with your body’s own hormone systems to change how hungry you feel, how full you get, and how your body handles blood sugar and fat storage. Here’s what the actual research says about each one, in plain English.
First, the science in one paragraph
All three are “incretin mimetics” — they copy hormones your gut naturally releases after eating.
- Retitrutide copies three: GLP-1, GIP, and glucagon.
- Tirzepatide copies two: GLP-1 and GIP.
- Semaglutide copies one hormone: GLP-1.
More hormone pathways generally means more metabolic firepower — which is a big part of why the newer drugs tend to outperform the older ones in head-to-head data, and why they matter specifically for a body that’s fighting menopausal insulin resistance and belly-fat accumulation.
1. Retatrutide — the newest, most powerful, and still has fascinating research data
Retatrutide is Eli Lilly’s triple-hormone agonist (GLP-1 + GIP + glucagon), and it is generating the most striking numbers ever seen in an obesity drug trial.
TRIUMPH-1 (the pivotal Phase 3 trial, topline results announced May 2026): Across 2,339 participants over 80 weeks, average weight loss was 17.6% (4 mg), 23.7% (9 mg), and 25.0% (12 mg), compared to 3.9% on placebo.
In an extension of people who tolerated treatment well, weight loss on the highest doses reached as much as 28–30% of body weight over roughly two years — territory previously associated almost exclusively with bariatric surgery.
Additional benefits from the TRIUMPH program:
- In TRIUMPH-4 (people with obesity and knee osteoarthritis), retatrutide reduced knee pain scores by about 76%, with some participants reporting complete pain relief, meaningful drops in triglycerides, non-HDL cholesterol, blood pressure, and inflammatory markers like hsCRP.
- In diabetes-focused trials (TRANSCEND-T2D-1), it also lowered HbA1c by up to 2.0 percentage points alongside weight loss.
The trade-off: Because it activates more pathways, retatrutide’s side-effect profile trends similar to the others (mostly GI-related) but also includes a mild, temporary increase in heart rate that researchers are monitoring closely.
Source: Eli Lilly, TRIUMPH-1 topline results, May 21, 2026; Jastreboff AM, et al. “Retatrutide for Obesity — A Phase 2 Trial,” NEJM, 2023; TRIUMPH-4 results, December 2025.
2. Tirzepatide (Zepbound / Mounjaro) — the one with menopause-specific data
The landmark trial: SURMOUNT-1, the pivotal trial published in NEJM, showed average weight loss of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) at 72 weeks, versus 2.4% on placebo. Up to 36% of participants on the highest dose lost 25% or more of their body weight — numbers that begin to approach surgical outcomes.
Why this one matters especially for you: A post-hoc analysis of SURMOUNT-1, -3, and -4 specifically broke results down by reproductive stage — premenopausal, perimenopausal, and postmenopausal women.
The findings were remarkably consistent across all three groups: across all reproductive stages, 97–98% of women lost at least 5% of body weight on tirzepatide, versus just 29–33% on placebo — and waist circumference dropped by roughly 20–22 cm versus 4–5 cm with placebo.
This tells us something important: hormonal stage doesn’t appear to blunt the drug’s effectiveness, which is genuinely reassuring for women worried menopause would make treatment less effective.
Head-to-head with semaglutide (SURMOUNT-5): In a direct trial comparing the two drugs, tirzepatide produced significantly greater weight loss (–20.2%) than semaglutide (–13.7%) over 72 weeks — the first trial to directly settle the “which one works better” question.
Body composition data: A DXA (bone density scan) substudy found that roughly 75% of the weight lost was fat mass, and only 25% was lean muscle — an important reassurance, since preserving muscle matters more as we age.
Source: Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM, 2022; Reproductive-stage subgroup analysis, Obesity, 2025; SURMOUNT-5, 2026.
3. Semaglutide (Wegovy / Ozempic) — the one that started it all
The landmark trial: STEP 1, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight — notably, 74% of participants were women, with an average age of 46, putting this squarely in the demographic of women navigating perimenopause.
The results: At 68 weeks, participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight, compared to 2.4% on placebo. Nearly 86% of women and men on semaglutide lost at least 5% of their starting weight, versus just 31.5% on placebo.
Longer-term data (STEP 5): Over two years, weight loss was sustained at –15.2%, with 77% of participants maintaining at least a 5% loss — showing this isn’t just a short-term water-weight effect.
The honest caveat: A STEP 1 extension study found that when people stopped the medication, they regained about two-thirds of the lost weight within a year, underscoring that obesity is treated as a chronic condition requiring ongoing management, not a one-time fix.
Specific benefits reported in the research:
- Significant reductions in waist circumference.
- Improved blood pressure, triglycerides, and blood sugar markers.
- Reduced risk of major cardiovascular events in a dedicated cardiovascular outcomes trial.
- Mostly mild-to-moderate GI side effects (nausea, constipation) that improve over time for most users.
Sources
Retatrutide
- Eli Lilly, TRIUMPH-1 topline results press release, May 21, 2026.
- Jastreboff AM, et al., “Retatrutide for Obesity — A Phase 2 Trial,” NEJM, 2023;389:514-526.
- Eli Lilly, TRIUMPH-4 topline results press release, December 11, 2025.
- Rheumatology Advisor / Healio coverage of TRIUMPH-4 knee osteoarthritis results.
- The Pharmaceutical Journal, “Phase III retatrutide study demonstrates 30% weight loss,” May 2026.
Tirzepatide
- Jastreboff AM, et al., “Tirzepatide Once Weekly for the Treatment of Obesity” (SURMOUNT-1), NEJM, 2022.
- Tchang BG, et al., “Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program,” Obesity, 2025;33:851-860.
- Eli Lilly, SURMOUNT-5 topline results press release, December 4, 2024.
- SURMOUNT-5 full results, NEJM, 2025/2026 (head-to-head vs. semaglutide).
Semaglutide
- Wilding JPH, et al., “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP 1), NEJM, 2021.
- Garvey WT, et al., STEP 5 two-year extension results, Nature Medicine, 2022.
- Wilding JPH, et al., “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension,” 2022 (PubMed/PMC).
None of the information contained in this article is medical advice. Please consult your own physician for any specific issues you may be having.